Connect your AI

Acadia Pharmaceuticals ACAD Earnings yield

Earnings yield at other companies

BiogenBIIB

5.3%-2.1pp

Neurocrine BiosciencesNBIX

5.1%+2.3pp

Catalyst PharmaceuticalCPRX

7.3%+0.6pp

PTC TherapeuticsPTCT

15.4%+10.2pp

BridgeBio PharmaBBIO

-5.1%-1.7pp

TG TherapeuticsTGTX

8.7%+8.1pp

Other financials

Income statement

Revenue$268.1M+9.7%

Gross profit$243.3M+8.6%

Operating income-$4.6M-124%

Net income$3.6M-80.8%

EPS (diluted)$0.02-81.8%

Balance sheet

Cash & equivalents$282.2M+29.6%

Total debt$50.8M-9.3%

Total equity$1.2B+63.1%

Total assets$1.6B+41.8%

Cash flow

Operating cash flow$34.0M+67.2%

CapEx$5.2M—

Free cash flow$28.8M+41.6%

Valuation

Market cap$3.87B+37.0%

Profitability

Gross margin91.5%-0.6pp

Operating margin7.4%-16.2pp

Net margin34.3%+11.3pp

FCF margin18.9%—

Returns & leverage

Return on equity37.3%+0.1pp

Debt / equity0×0.0×

Current ratio3.6×+0.7×

Where this comes from

Calculated from Acadia Pharmaceuticals’s reported figures.

net income/market cap=9.9%

Based on trailing twelve months.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Acadia Pharmaceuticals's earnings yield?: Acadia Pharmaceuticals (ACAD) reported earnings yield of 9.9% in Q1 2026.
How has Acadia Pharmaceuticals's earnings yield changed year-over-year?: Acadia Pharmaceuticals's earnings yield increased by 19.8% year-over-year, from 8.3% to 9.9%.
What is the long-term trend for Acadia Pharmaceuticals's earnings yield?: Over 5 years (2020 to 2025), Acadia Pharmaceuticals's earnings yield has grown at a 21.4% compound annual growth rate (CAGR), from -3.3% to 8.7%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.